Target family: Catecholamine turnover (type: enzyme)
Target: Monoamine oxidase A

Ligand: befloxatone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
Published in: J Affect Disord

Ligand: bifemelane (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Japan only
Primary target: no
Median affinity: 5.380000114440918 pKi
Reference (Journal): 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.
Published in: J Neurochem

Ligand: clorgiline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: CR4056 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.690000057220459 pIC50
Reference (Journal): Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.
Published in: J Pain Res

Ligand: harmaline (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.480000019073486 pIC50
Reference (Journal): Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
Published in: Eur J Med Chem

Ligand: harmaline (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
Published in: J Med Chem

Ligand: linezolid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2000), UK (2001)
Primary target: no
Median affinity: 4.340000152587891 pIC50
Reference (Journal): Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives.
Published in: Eur J Med Chem

Ligand: moclobemide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity: 8.300000190734863 pKi
Reference (Journal): Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
Published in: Bioorg Med Chem Lett

Ligand: phenelzine (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: yes
Median affinity: 7.329999923706055 pKi
Reference (Journal): Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B.
Published in: Biochemistry

Ligand: pirlindole (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: Russia only
Median affinity:  -
Reference (Journal): The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding.
Published in: J Neural Transm Suppl

Ligand: selegiline (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: no
Median affinity: 4.170000076293945 pKi
Reference (Journal): Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.
Published in: Bioorg Med Chem Lett

Ligand: tranylcypromine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1961)
Primary target: yes
Median affinity: 4.699999809265137 pIC50
Reference (Journal): Fluorinated phenylcyclopropylamines. Part 3: Inhibition of monoamine oxidase A and B.
Published in: Bioorg Med Chem